Sections
Log in
Top News
U.S. News World News Featured Voices
Odd News
Entertainment
Movies Music TV
Sports
Soccer NFL NBA MLB NHL Golf Horse Racing Tennis Col. Football Col. Basketball
Photos
News Entertainment Sports Features Archives
More...
Defense Featured Science Health Archive Almanac
About Feedback
About Feedback
Search
Trending
Julian Edelman
EPA
Venezuela
Push-up test
Saudi prisoners
AAF
Anthony Weiner
Darren Criss
Denny Hamlin
Amazon
Airplane birth
Health News
June 8, 2015 / 7:06 PM

Transplant anti-rejection drug protects against Alzheimer's, study says

By
Stephen Feller
A drug used to prevent transplant patient's bodies from rejecting their new organs may help prevent Alzheimer's disease. Photo by Fresnel/Shutterstock

GALVESTON, Texas, June 8 (UPI) -- A drug that suppresses the immune system to prevent transplant patient's bodies from rejecting their new organs may prevent Alzheimer's disease.

Researchers made the discovery while reviewing data that showed that dementia and Alzheimer's occur among transplant patients at much lower rates than in the general population.

Calcineurin, an enzyme that regulates communication between brain cells and memory formation, plays a major role in the formation of toxic protein aggregates that target and disrupt the brain cells responsible for memory among Alzheimer's patients.

"These data clearly show that the prevalence of dementia and Alzheimer's in our transplant patient group is significantly lower, in fact almost absent, when compared to national data from the general population," Luca Cicalese, a professor in the department of surgery, said in a press release.

Calcineurin inhibitor-based medications, such as Tacrolimus or cyclosporine, are taken by transplant recipients to suppress the immune system and prevent rejection of the new organs. Researchers must still find a way to block calcineurin, potentially benefitting Alzheimer's patients, without affecting the immune system.

"We are currently working on devising treatment strategies to obtain the same beneficial effects in AD humans using low doses of calcineurin inhibitors that result in minimal or no immunosuppression, thus limiting possible undesired side effects," said Giulio Taglialatela, Professor and Vice Chair for Research in the department of neurology and director of UTMB's Mitchell Center for Neurodegenerative Diseases.

The study is published in the Journal of Alzheimer's Disease.

Read More

Mice saved from flu by drug protecting their lungs Stem cell transplant may return sense of touch Scientists discover how breast cancer travels in the body
  • Topics
  • Alzheimer's Disease
Follow us on Facebook, Twitter and Instagram for more UPI news and photos.

Trending Stories

Number of push-ups men can do in a row may indicate heart health
HPV unlikely to be spread by hands, researchers say
Study: Chemical in Roundup may increase cancer risk by 40 percent
FDA approves first customizable insulin pump
Hip and knee replacements show high durability, study shows

Photo Gallery

 
Balloons take flight at Al-Ula Balloon Festival in Saudi Arabia

Latest News

Dollar store herbal water for infants recalled due to choking hazard
Boeing to deliver two F-18 Super Hornets to Navy for $17.8M
Italian interior minister faces kidnap charges for refusing migrant ship
Monsta X releases new album, 'Alligator' music video
Israeli-European summit canceled after Holocaust remarks about Poland
 
Back to Article
/
Back to top
About UPI Contact Feedback Advertisements Submit News Tips
Copyright © 2019 United Press International, Inc. All Rights Reserved.
Terms of UsePrivacy Policy